Society for Immunotherapy of Cancer 27th Annual Meeting
October 26-28, 2012 North Bethesda, Maryland
The SITC 27th Annual Meeting allows for scientific exchange of the most cutting-edge preclinical and clinical data on immunotherapies and biological therapy of cancer. The program included dynamic presentations, interactive panel discussions and scientific posters on the most timely topics in cancer immunotherapy as well as vital information on clinical trial design and regulatory issues to advance collaboration and translation of cancer immunotherapies.
SITC is ideally positioned to meet the identified needs of our attendees. SITC’s strength lies in its history of organizing successful scientific conferences that gather clinicians and scientists from around the globe to interact and discuss the most important issues in cancer immunotherapy. By addressing these needs, SITC advances effective, efficient research and interaction on promising cancer therapies with biological and immunological agents. Through its integrated programs, SITC promotes productive collaboration among scientists and with other organizations in the field. Ultimately this scientific exchange and collaborative environment will lead to better cancer patient outcomes with novel cancer immunotherapies.
The SITC 27th Annual Meeting program format and content is designed to address identified needs/practice gaps and promotes:
Exchange between basic and clinical researchers, thus improving the caliber of the science and promoting translation
Discussion on potential hurdles in cancer immunotherapy from the trial design and regulatory perspective
Integrated understanding of the state of cancer immunotherapy research in today’s environment, identification of potential funding opportunities, and mentoring of junior investigators
Discussion of novel therapies and applications based on the research presented
Interactions with industry to promote access to novel agents for clinical development
Intended Audience
The audience for this program is basic and clinical investigators from academic institutions, industry and regulatory agencies, including clinicians, basic and translational researchers, graduate students, postdoctoral fellows, and allied health professionals involved in cancer research.
Program Goals
Exchange information on the most recent advances in tumor immunology and cancer immunotherapy
Convey recent advances in biology and immunotherapy as they relate to specific cancers and various immunotherapy modalities, cell subsets, animal models, and aspects of negative regulation in the tumor microenvironment
Identify promising research opportunities, new techniques and clinical applications incorporating these advances
Establish dialogue between academia, industry and government on these advances
Expected Learner Outcomes
Upon completion of this program, the participants will be able to:
Summarize the most recent advances in tumor immunology and cancer immunotherapy
Integrate recent advances in cancer immunology and immunotherapy into basic, clinical and translational research
Incorporate new research and techniques into clinical applications for cancer immunotherapy
Establish and solidify collaborations among the various members of academia, industry, government and clinical practices to promote clinical evaluation of these advances in more efficient trials
